The Phase 2 trial results indicate median overall survival rates of 39.3 months for patients with a combined positive score (CPS) of 20 or higher, and 30.0 months for patients with a CPS of 1 or ...

Burtness B. et al. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell ...

Home News GlobeNewswire Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 ...